Castle Biosciences is a molecular diagnostics and prognostics company dedicated to helping patients and physicians make optimal decisions regarding treatment and follow-up care based on the tumor's unique molecular signature. The Company currently offers prognostic tests for patients with rare cancers including uveal and cutaneous melanoma, esophageal, thymoma and brain cancers as well as malignant pleural mesothelioma.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/13/14 | $11,800,000 |
HealthQuest Capital Longfellow Venture Partners Mountain Group Capital | undisclosed | |
| 07/27/15 | $11,700,000 | Series F |
HealthQuest Capital Industry Ventures Mountain Group Capital | undisclosed |
